MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/17534666241308406

Медицинская библиотека · Therapeutic advances in respiratory disease · 2025

A real-world study to evaluate effectiveness of mepolizumab in treating severe asthma in Taiwan (REMIT).

Cheng Shih-Lung, Lin Shu-Min, Peng Chung-Kan, Chan Ming-Cheng, Shen Sheng-Yeh, Kuo Ping-Hung, Lai Chien-Hao, Lan Chou-Chin, Chen Chung-Yu, Lin Ching-Hsiung, Liao Kuang-Ming, Feng Po-Hao, Wu Jiin-Torng, Wei Yu-Feng, Xu Xiaomeng, Alfonso-Christancho Rafael, Lai Tina, Navarro Aldo, Milea Dominique, Perng Diahn-Warng

СтатьяНаблюдательное исследованиеМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

REMIT is the first real-world study of mepolizumab effectiveness in patients with severe asthma (SA) in Taiwan.

OBJECTIVES

The primary objective evaluated changes in clinically significant exacerbations (CSEs; defined as use of oral corticosteroids (OCS) or emergency department (ED) visits and/or hospitalizations) in the 12 months pre- and post-mepolizumab treatment. Secondary objectives assessed changes in the number of CSEs requiring ED visits/hospitalizations and daily maintenance OCS (mOCS) dosage 12 months pre- and post-mepolizumab treatment. Three- and four-component clinical remissions were analyzed based on OCS-free, exacerbation-free, and asthma control (± stability in lung function).

DESIGN

REMIT was a retrospective, observational, self-controlled study analyzing patients in Taiwan with SA who were newly prescribed subcutaneous mepolizumab 100 mg Q4W.

METHODS

Data were extracted from records of 15 medical centers in Taiwan for patients indexed between November 1, 2018 and October 31, 2020.

RESULTS

A total of 170 patients were included: mean age at index date, 58.7 years; 53.5% female; 100% Chinese; 7.1% with chronic rhinosinusitis with nasal polyps, 1.8% with eosinophilic granulomatosis with polyangiitis, 1.2% with hypereosinophilic syndrome; and 55.7% with blood eosinophil count >300/µL. Pre-treatment, 71.2% had ⩾2 exacerbations, and 28.7% were on mOCS; 75.3% had no prior biologic treatment, and 24.7% had switched from other biologics. Most patients (80.0%) completed ⩾10 mepolizumab doses. Following the first mepolizumab administration (index date), CSEs reduced by 46.0% (rate ratio (RR): 0.545, 95% confidence interval (CI): 0.418-0.710; p < 0.0001) in the 12 months post-index. Exacerbations requiring ED visits/hospitalization reduced by 46.9% (RR: 0.531, 95% CI: 0.349-0.808; p = 0.0031). Median mOCS dose reduced by 100% by end of study and 81.8% of patients discontinued mOCS post-treatment. After 1 year of mepolizumab treatment, 28% and 23% patients achieved three- and four-component clinical remission, respectively.

CONCLUSION

Mepolizumab use in a patient population in Taiwan with SA significantly reduced CSEs and mOCS use in routine clinical practice.

Для цитирования: Cheng Shih-Lung, Lin Shu-Min, Peng Chung-Kan, Chan Ming-Cheng, Shen Sheng-Yeh, Kuo Ping-Hung, Lai Chien-Hao, Lan Chou-Chin, Chen Chung-Yu, Lin Ching-Hsiung, Liao Kuang-Ming, Feng Po-Hao, Wu Jiin-Torng, Wei Yu-Feng, Xu Xiaomeng, Alfonso-Christancho Rafael, Lai Tina, Navarro Aldo, Milea Dominique, Perng Diahn-Warng. A real-world study to evaluate effectiveness of mepolizumab in treating severe asthma in Taiwan (REMIT).. Therapeutic advances in respiratory disease. 2025. DOI: 10.1177/17534666241308406.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.